IRVINE, Calif., June 4, 2009 (GLOBE NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO), a leading provider of medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, announced today that it will participate in a "Virtual" Conference hosted by Lazard Capital Markets (LCM) on Wednesday, June 10, 2009 at 2:00 p.m. EDT/11:00 a.m. PDT. The conference call and webcast is an Addendum to LCM's Radiation Oncology Day, which is being held the previous day in New York on June 9, 2009. Lloyd Malchow, President and Chief Executive Officer, will be joined by Paul Lubock, Senior Vice President and Chief Technology Officer for the Virtual Conference.
SenoRx invites investors and those interested to listen to the live webcast of this presentation via the Internet on the Investor Relations section of the company's Web site http://investor.senorx.com/events.cfm. A webcast replay of the call will be available on the company's web site approximately 90 minutes after the call concludes.
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605